Phaseline

Targets › GCDH

GCDH (Glutaryl-CoA dehydrogenase, mitochondrial): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout Aug 2027.

Catalyzes the oxidative decarboxylation of glutaryl-CoA to crotonyl-CoA and CO(2) in the degradative pathway of L-lysine, L-hydroxylysine, and L-tryptophan metabolism. It uses electron transfer flavoprotein as its electron acceptor. (UniProt, Q92947)

Open in Phaseline: the race on GCDH, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Shanghai Vitalgen BioPharmaVGM-R02b
rAAV9-mediated GCDH gene replacement therapy
GCDHPhase 1Glutaric Acidemia Type IAug 2027

Conditions

Glutaric Acidemia Type I (1)

Modalities

protein or peptide (1)

Companies

Shanghai Vitalgen BioPharma (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.